S&P Global Ratings has upgraded the long-term issuer credit rating of Biocon Biologics Limited to 'BB+' from 'BB' and revised ...

Biocon Limited board approves QIP at ₹387.74 per share, with issue opening on 12 January 2026 and new oncology biosimilars announced.

Biocon recently unveiled three new biosimilar oncology assets to its R&D pipeline —trastuzumab/hyaluronidase (Herceptin ...

Pharma major Biocon is set to announce its Q3FY26 results on 12 Feb 2026. Brokerage reports project a strong Q3FY26 for ...

Biocon Biologics Limited, a fully integrated, global biosimilars company and subsidiary of Biocon announced that S&P Global Ratings has upgraded the company’s long-term issuer credit rating to ‘BB+’ ...

Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes. The Food and Drug Administration has given Biocon Ltd.’s wholly owned ...

Pharma stocks rise as Cipla faces supply issues, Zydus gains FDA approval, and Biocon secures funding through a QIP.

Biocon Pharma receives USFDA approval for generic Everolimus tablets, used to treat tuberous sclerosis complex (TSC).

In an exchange filing, the company said the approval covers Everolimus Tablets for Oral Suspension in 2 mg, 3 mg and 5 mg strengths.

Biocon said that proceeds from the QIP will be primarily utilised to meet the cash consideration payable to Mylan Inc.